Inmune Bio Files Proxy Statement for July 19th Shareholder Meeting

Ticker: INMB · Form: DEF 14A · Filed: May 29, 2024 · CIK: 1711754

Inmune Bio, Inc. DEF 14A Filing Summary
FieldDetail
CompanyInmune Bio, Inc. (INMB)
Form TypeDEF 14A
Filed DateMay 29, 2024
Risk Levellow
Pages14
Reading Time17 min
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

Related Tickers: INMB

TL;DR

INMB proxy filed, shareholder meeting July 19. Vote on directors & auditors.

AI Summary

Inmune Bio, Inc. filed its definitive proxy statement on May 29, 2024, for its annual meeting of stockholders scheduled for July 19, 2024. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key items likely include the election of directors and ratification of auditors.

Why It Matters

This filing provides shareholders with crucial information regarding company leadership and voting matters, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing information to shareholders and does not inherently introduce new business or financial risks.

Key Players & Entities

  • Inmune Bio, Inc. (company) — Registrant
  • 0001213900-24-047456 (filing_id) — Accession Number
  • 20240529 (date) — Filing Date
  • 20240719 (date) — Meeting Date

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with the proxy statement for Inmune Bio, Inc.'s annual meeting of stockholders.

When is the scheduled date for Inmune Bio, Inc.'s annual meeting of stockholders?

The annual meeting of stockholders is scheduled for July 19, 2024.

Who is the filer of this proxy statement?

The filer of this proxy statement is Inmune Bio, Inc., the Registrant.

What is the Central Index Key (CIK) for Inmune Bio, Inc.?

The Central Index Key (CIK) for Inmune Bio, Inc. is 0001711754.

What is the business address of Inmune Bio, Inc.?

The business address of Inmune Bio, Inc. is 225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL 33432.

Filing Stats: 4,157 words · 17 min read · ~14 pages · Grade level 12.2 · Accepted 2024-05-29 16:05:10

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION   19       Summary Compensation Table   19 Employment Agreements   19 Consulting Agreement   19 Securities Authorized for Issuance Under The Equity Compensation Plan   20 i Table of Contents OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END   21       DIRECTOR COMPENSATION   22       TRANSACTIONS WITH RELATED PERSONS   23       Procedures for Approval of Related Party Transactions   23 Interests of Certain Persons in Matters to be Acted Upon   23       STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF INMUNE BIO INC.   24       HOUSEHOLDING OF MATERIALS   25       STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING   25       OTHER MATTERS   26       ANNUAL REPORT   26 ii Table of Contents QUESTIONS AND ANSWERS The following are some questions that you, as a stockholder of the Company, may have about the Meeting, the proposals being considered at the Meeting, as applicable, and brief answers to those questions. These questions and answers may not address all questions that may be important to you as a stockholder of the Company. We encourage you to read carefully the more detailed information contained elsewhere in this proxy statement. Q:       Why am I receiving this proxy statement? A:       These proxy materials describe the proposals on which the Company would like you to vote and also give you information on these proposals so that you can make an informed decision. We are furnishing our proxy materials to all stockholders of record entitled to vo

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.